The Biden administration is rescinding ex-President Trump's unimplemented most favored nation drug pricing rule, which was disliked by 340B entities and drug manufacturers.

Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked

The Biden administration is rescinding an unimplemented Trump-era regulation that would have pegged Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers provide in similar countries.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report